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Abstract: Introduction: Internal Cardioverter Defibrillators (ICD) has been shown to decrease mortality in patients such 
as those with structural heart disease or at high risk of sudden cardiac death. To date there is no data regarding the clinical 
features, and outcomes of ICD patients in Saudi Arabia. Accordingly, we explored the clinical features and outcomes of 
ICD therapy among Saudis. 
Methods: Patients who had ICD implantation in King Khalid University Hospital from November 2007 until January 2010 
were enrolled. 
Results:  One hundred and eight ICD were implanted between November 2007 and February 2010. The mean age   
was 58.6±13.2 years. The majority were male 94 (87%), the rate of Diabetes Mellitus (DM) was 58.3%, Hypertension 
(HTN) was 61.1%, and 63% were smokers. The mean ejection fraction (EF) was 24.5%. Of the 108 patient 90(83.3%)  
had ICD insertion for primary prevention and 18(16.7%) for secondary prevention. Of the 90 patients who ICD for  
primary prevention 62 (57.4%) had ischemic cardiomyopathy, 39(36.1%) had dilated cardiomyopathy and 7 (6.5%) had 
channelopathy. Over a mean follow-up of 18 months 4 (3.7%) died 
Conclusions: Our study describes for the first time patients characteristic and outcomes for ICD therapy in Saudi Arabia. 
Our patients are younger and have higher prevalence of risk factors that those in Western countries. 
Keywords: Implantable Cardioverter-Defibrillator, Saudi Arabia.  
INTRODUCTION 
  The implantable cardioverter defibrillator (ICD) provides 
a remarkably effective therapy for ventricular tachycardia 
(VT) and ventricular fibrillation (VF). Several large, multi-
center, randomized clinical trials showed that an ICD is su-
perior to antiarrhythmic drugs in the secondary prevention of 
sudden cardiac death (SCD) [1-4]. Furthermore, ICD therapy 
is well-established for primary prevention of SCD, and im-
proves survival in patients with structural heart disease [1, 3-
6]. To date, no data are available on characteristics and out-
comes of recipients receiving ICD therapy in Saudi Arabia. 
In the ACC/AHA/HRS 2008 Guidelines for Device-Based 
Therapy of Cardiac Rhythm Abnormalities, areas in need of 
further research included identifying and describing “long-
term outcomes and risk factors for patients receiving ICDs in 
general practice compared with trial populations and at aca-
demic centers [1]. Accordingly, our objective was to explore 
clinical features and outcomes of ICD therapy recipients 
during a 2-year interval in a single academic center in Saudi 
Arabia. 
METHODS 
  Patients who had ICD implantation at King Khalid   
University Hospital in Riyadh, Saudi Arabia, from December  
 
*Address correspondence to this author at the Department of Cardiac   
Sciences, College of Medicine, King Saud University, Riyadh KSA,  
Tel: +96614671161; Fax: +9664671158; E-mail: ahersi@ksu.edu.sa 
2007 through January 2010 were included in this analysis. 
Data on patient demographics, clinical history and indication 
for implantation of the ICD, device type, incidence of 
shocks, antiarrhythmic medication use, and total mortality 
were collected. Left ventricular ejection fraction (LVEF) was 
determined using the Simpson method or by ventriculogra-
phy during cardiac catheterization. All patients had trans-
venous ICD insertion via the left axillary vein. None (the 
electrophysiological study is not anymore a pre-request to 
ICD insertion as per the guidelines) had an electrophysi-
ological study (EPS) prior to ICD implantation. Patients 
were required to have Class I indication for ICD therapy as 
per AHA/ACC/ESC guidelines [1]. In brief, patients quali-
fied for ICD therapy who had: 1) ischemic cardiomyopathy 
(IC), 40 days post myocardial infarction (MI), NYHA func-
tional Class I, and LVEF 30%; 2) IC, 40 days post MI, 
NYHA Class II or II, and LVEF 35%; 3) dilated cardiomy-
opathy (DCM) with LVEF 35% and NYHA Class II or III; 
4) 40 days post-MI, LVEF 40%, and with nonsustained 
VT and VF or VT inducible at EPS; or 5) cardiac arrest 
without identifiable reversible cause. After implantation, 
patients were followed-up regularly in our device clinic. 
Shocks were documented by device interrogation and con-
firmed by an electrophysiologist.  
  Statistical analysis: Continuous variables were summa-
rized as mean ± standard deviation or median and inter-
quartile range (IQR), as appropriate and categorical variables 
was summarized as percentages. Group differences between Implantable Cardioverter Defibrillator Therapy  The Open Cardiovascular Medicine Journal, 2010, Volume 4    193 
categorical variables were analyzed with chi square or Fisher 
exact test, and between normally distributed continuous vari-
ables using Student’s t test. For all analyses, p<0.05 was 
considered significant. Analysis was performed using SPSS 
version 17. 
RESULTS 
  From December 2007 through January 2010, 108 ICD 
implantations were performed. The majority of patients (n = 
94; 87%) were male, and there was a high prevalence of dia-
betes mellitus (DM: n = 63; 58.3%), hypertension (HTN: n = 
66; 61.1%), dyslipidemia (n = 51; 47.2%), smoking (n = 68; 
63%), and history of previous MI (n = 57; 52.8%) (Table 1). 
The mean LVEF was 24.6 ± 9.43. The majority were in sinus 
rhythm (n = 86; 79.6%), and 22 (20.4%) were in atrial fibril-
lation (AF). Sixteen (14.8%) were NYHA Class I, 64 
(59.3%) were Class II, and 28 (25.9%) were Class III. Of the 
108 implantations, 90 (83.3%) were for primary prevention, 
and 18 (16.7%) were for secondary prevention. The patients 
who had ICD therapy for primary prevention were more 
likely to have ischemic cardiomyopathy (n = 53; 58.9%) than 
DCM (n = 35; 38.9%: p=0.003) Table 2. Of the patients who 
had ICD for secondary prevention, 7 (38.9%) had VT with 
syncope, 8 (44.4%) had cardiac arrest, 2 (11.1%) had long 
QT syndrome, and 1 (5.5%) had Brugada syndrome. Ninety-
two (85.2%) patients had single chamber and 16 (14.8%) had 
dual chamber ICDs implanted. Over a mean follow-up of 
13.4 ± 9.5 months, 12 patients (11.1%) had ICD shocks, 8 
(66.7% of shocks; 7.4% of patients) of which were classified 
as appropriate and 4 (33.3% of shocks, 3.7% of patients) as 
inappropriate. Seven of the appropriate shocks were in pa-
tients with VVI-ICD (7.6% of VVI patients) and one in a 
patient with DDD-ICD (6.3% of DDD patients). Appropriate 
shocks occurred in 5 patients with IC and 3 with DCM. The 
4 inappropriate shocks were in patients with VVI-ICD (4.3% 
of VVI patients), 2 of whom had IC and 2 DCM.  
  All-cause mortality was 3.7% (n=4); all patients who 
died had IC, and the indication for implantation was primary 
prevention, resulting in a 4.4% mortality rate in that group. 
The 4 deaths were male, with single chamber ICD, one was 
in NYHA Class II and 3 were NYHA Class III, 1 was in AF 
and 3 were in sinus rhythm. None of the deaths occurred in 
patients experiencing shocks. 
DISCUSSION 
  Data from multiple clinical trials support the use of ICDs 
for both primary and secondary prevention of SCD. Several 
risk factors were used to identify purported high-risk popula-
tions to include in those studies [7]. Three large, early RCTs 
investigating secondary prevention (AVID, CASH, CIDS) 
enrolled patients who had at least survived VT/VF/cardiac 
arrest. Although the ICD groups in each study had reduced 
total mortality, the difference was significant only in the 
AVID study. The appropriateness of the study risk factors 
used for eligibility was questioned, however, when a registry 
of patients not meeting AVID eligibility criteria had worse 
survival than AVID ICD patients [8] Primary prevention 
trials had more variable inclusion criteria, and, despite dif-
ferences in design among the trials, 7 of 9 major trials dem-
onstrated the benefits of ICD therapy [7] The current guide-
lines on the use of ICDs are based on a writing committee 
consensus that ICD patients should have clinical profiles 
closely aligned with those of patients included in those clini-
cal trials; [1] while the controversy over ideal patient charac-
teristics remains, with others reporting that the benefit of 
ICDs also includes populations not represented in the trials 
[4].  
Table 1.  Patient Characteristics and Therapy 
Variable   n (%) 
Age, mean years ± SD  58.6 ± 13.2 
Gender (Male)  94 (87.0) 
DM 63  (58.3) 
HTN 66  (61.1) 
Dyslipidemia 51  (47.2) 
Stroke 3  (2.8) 
Smoker 68  (63.0) 
MI 57  (52.8) 
EF (mean ± SD)  24.6 ± 9.43 
Cardiomyopathy: 
Ischemic   62 (57.4) 
DCM 39  (36.1) 
Other 7  (6.5) 
ICD Indication: 
Primary   90 (83.3) 
Secondary 18  (16.7) 
Secondary Prevention: 
VT with syncope  7 (38.9) 
Post cardiac arrest  8 (44.4) 
Long QT  2 (11.1) 
Burgada 1  (5.6) 
Device Type: 
VVI - ICD  92 (85.2) 
DDD - ICD  16 (14.8) 
Shocks 12(11.1) 
Appropriateness 8  (66.6) 
NYHA: 
Class I  16 (14.8) 
Class II  64 (59.3) 
Class III   28 (25.9) 
Class IV  0 
Rhythm: 
SR 86  (79.6) 
AF 22  (20.4) 
Death 4  (3.7) 194    The Open Cardiovascular Medicine Journal, 2010, Volume 4  Ahmad S. Hersi 
Table 1. contd…. 
Variable   n (%) 
Medications: 
Beta-Blocker 80  (74.1) 
Digoxin   45 (41.7) 
ACE-I 95  (87.9) 
ARB 14  (13.0) 
Statin 98  (90.7) 
Diuretics 92  (85.2) 
Aspirin 92  (85.2) 
Plavix 60  (55.5) 
Warfarin 10  (9.3) 
Nitrate 23  (21.3) 
Spironolactone 39  (36.1) 
Amiodarone 12  (11.1) 
KEY: AF – atrial fibrillation; EF – ejection fraction; ICD - ; SR – sinus rhythm; 
  LVEF values in the major trials were summarized in a 
recent systematic review that included 12 efficacy RCTs [4]. 
Patient LVEF ranged from 21% to 28% in primary preven-
tion studies, and 32% to 46% in secondary prevention trials. 
In addition, results from 53 observational effectiveness stud-
ies were reviewed, which included patients with mean LVEF 
ranging from 19% to 46%. The mean LVEF of 25% for our 
patients was within the ranges of the primary prevention 
RCTs and the observational studies. However, recent studies 
and commentaries emphasize the importance of identifying 
risk stratification tools in addition to EF that can be used in 
the selection of patients suitable for ICD implantation, and 
remind that not all patients whose EF is 30% are proper 
candidates for ICDs [9] In addition, when data from the 
MUSTT trial were analyzed for the relationship of EF and 
inducible ventricular tachyarrhythmias with the mode of 
death, results suggested that ICDs may reduce mortality in 
patients whose EF is 30% as well as in those with lower EF 
[10].  
  Several reports investigated outcomes in patients who 
met the inclusion criteria of the major studies. For example, 
a Japanese study retrospectively evaluated data from 90 pa-
tients who did not have ICD implantation, but who had the 
Table 2.  Patients Stratified Based on the Underlying Heart Disease  
Variable  Ischemic Cardiomyopathy 62(57.4)  DCM 39(36.1)  P-value 
Age 60.8±11.3  57.2±14.0  0.15 
Gender(male) 59(95.2)  32(82.1)  0.037 
DM 52(57.8)  11(61.1)  0.50 
HTN 41(66.1)  20(51.3)  0.10 
Dyslipidemia 34(54.8)  16(41.0)  0.12 
Stroke 1(1.6)  2(5.1)  0.37 
Smoker 45(72.6)  22(56.4)  0.07 














EF 23.8±7.5  22.1±5.3  0.29 
ICD indication 
Primary 53(85.5)  35(89.7)  0.38 
Secondary 9(14.5)  4(10.3)  0.38 
Shocks 7(11.3)  5(12.8)  0.08 
Appropriate shocks  5(8)  3(7.7)  0.3 
Death 4(6.5)  0(.0)  0.12 
DM (diabetes mellitus); HTN (hypertension); MI(myocardial infarction); EF(ejection fraction). Implantable Cardioverter Defibrillator Therapy  The Open Cardiovascular Medicine Journal, 2010, Volume 4    195 
primary prevention RCT MADIT II criteria that included Q-
wave MI >4 weeks prior, LVEF <30%, and age >21 years 
[11]. Survival rates were similar to the ICD group in MADIT 
II, and greater than the conventional therapy group. How-
ever, most patients (79%) were in NYHA functional Class I, 
compared with 35% and 39% of MADIT-II ICD and con-
ventional therapy patients, respectively [12]. The authors 
concluded that MADIT-II criteria may be inappropriate for 
Japanese patients; however, the efficacy of ICDs in Class I 
patients is not known [1]. In another study, in fact, subgroup 
analysis of data from 459 patients randomly assigned to 
standard therapy or standard therapy plus an ICD revealed 
that LVEF 20%, male gender, and NYHA Class III but not 
Class I or II, were significantly associated with improved 
survival [13]. A Brazilian study compared 102 patients who 
did not receive an ICD to patients in the placebo arm of an-
other major primary prevention study, SCD-HeFT, and 
found that the mortality rates were similar between the 2 
groups, causing them to conclude that their patients were 
similar, and may benefit from ICD therapy if economic con-
straints could be removed [14]. Likewise, our patients shared 
several similarities with the RCT patients; for example age, 
gender, proportion of patients with ischemic cardiomyopa-
thy, and distribution among NYHA functional classes was 
similar to those in the 12 RCTs included in the systematic 
review by Ezekowitz et al. [4]  
  The 3.7% mortality in our entire cohort during a mean 
follow-up of 13 months is less than that reported in the 11 
controlled observational studies included in the systematic 
review of Ezekowitz et al., where 19 to 1442 patients in each 
study received an ICD [4]. In follow-up intervals of 12 to 
132 months in those studies, all-cause mortality ranged from 
6.8% to 36.8%, with a pooled reduction in all-cause mortal-
ity in ICD patients of 46%, which was greater than the 20% 
reduction in 9 pooled RCTs [4] All deaths in our study were 
in patients treated for primary prevention, and the resulting 
4.4% all cause mortality in these patients is less than the 
12.3% to 26.0% in the 9 primary prevention RCTs in the 
review. Reduced mortality in ICD patients in observational 
studies compared with RCTs was suggested by Ezekowitz  
et al. to indicate that practicing clinicians select healthier 
patients for ICD insertion [4]. 
  Although ICD effectiveness depends on the device being 
able to deliver appropriate shock therapy, both therapeutic 
and inappropriate shocks in patients with ICDs have been 
shown in several studies to seriously impact quality of life, 
resulting in decreased physical functioning and mental well-
being, and increased anxiety that may reach the point of 
panic disorder or agoraphobia [15]. In fact, in a recent report 
from China, 1 of 7 deaths following ICD implantation was a 
suicide response to emotional stress after multiple shocks 
were received during an electrical storm [16]. Appropriate 
shocks can be caused by ventricular fibrillation, monomor-
phic ventricular tachycardia, polymorphic ventricular tachy-
cardia, and Torsades de pointes [15]. From 5% to 12% of 
trial participants received an appropriate shock per year, with 
reports that it can increase to 30% of patients by 3 years [4, 
17, 18]. In our study, 7.4% of patients received an appropri-
ate shock, which is much less than the 25% to 33% reported 
in several other observational studies [4]. Brignole [19]   
emphasizes that “appropriate” and “necessary” shocks are 
not synonymous, and notes that the low number of patients 
receiving appropriate shocks was twice the mortality rate in 
control groups in 2 reports [20].  
  Rates of inappropriate discharges were reported at 19.1 
per 100 patient years in 2 RCTs, and 4.9 per 100 patient-
years in 27 observational studies [4]
  In fact, inappropriate 
shocks are the most common complication associated with 
ICD therapy [21]. In one study of 778 patients receiving 
ICDs, 13% received an inappropriate shock in follow-up 
averaging 4 months [22]. These shocks are most commonly 
due to misdiagnosis of atrial fibrillation or other supraven-
tricular tachycardias, and can also result from double count-
ing, atrial flutter, multiple premature ventricular contrac-
tions, oversensing of T waves or diaphragmatic myopoten-
tials, oversensing due to lead failure or insulation break, 
electromagnetic interference, and ectopy [23]. Mortality is 2- 
to 5-fold increased in patients who have ICD shocks [17, 
19]. This exemplifies the “conversion hypothesis;” that is, 
patients who are saved from sudden cardiac death by   
successful shocks may be at high risk of death from other 
cardiovascular-related causes [24]. Mishkin et al. report that 
the time from the first ICD shock to death is related to   
the appropriateness of ICD therapy as well as heart failure 
etiology, and occurs after a median interval ranging from 
168 to 294 days [17].  
  Our 2-year data revealed that single-chamber devices are 
primarily used (85.2% of patients) in our institution. Procle-
mer et al. evaluated data in the Italian Pacemaker Registry 
and found dual chamber devices in higher use than single 
chamber devices, with increasing trends toward use of dual 
chamber devices, similar to trends reported in the world sur-
vey [25]. They noted that this was despite a meta-analysis 
that failed to show a heart failure or overall mortality benefit 
between the 2 types [26]. In fact, of the 9 RCTs reviewed by 
Ezekowitcz, only 2 (MADIT-II and COMPANION) evalu-
ated dual chamber devices [4] .Of 20 observational studies of 
effectiveness that reported the type of device used, 18 in-
cluded both single- and dual-chamber devices, and one each 
included only single or dual. Ezekowitcz highlighted the 
paucity of data on dual chamber devices, remarking that, in 
addition to 3 observational studies and 1 RCT that failed to 
show benefit, an RCT suggested that the device can exacer-
bate heart failure in patients implanted with the dual cham-
ber device without an indication, such as such as chro-
notropic incompetence, sick sinus syndrome, or atrioven-
tricular conduction abnormalities [27]. There is some evi-
dence to suggest, however, that dual chamber ICDs may be 
associated with fewer inappropriate shocks [28, 29]. In a 
recent RCT in which 85% of patients had indications for 
secondary prevention, 3% and 12% of patients with dual and 
single-chamber ICDs, respectively, experienced inappropri-
ate shocks in a mean follow-up of 16 months [27]. In our 
small sample, 4.3% of patients with single-chamber ICDs 
had inappropriate shocks. While none of the 16 patients with 
dual-chamber ICDs had inappropriate shocks, the numbers 
are too small to allow a valid comparison, which should be-
come possible with the acquisition of additional data on 
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  This study has several limitations and benefits. In addi-
tion to limitations inherent in observational studies, the small 
numbers reflect that we are just beginning to collect data 
from a single center. Also, we do not have control group 
comparisons at this time. However, we are continuing to 
collect data, and intend to expand participation to include 
other centers in Saudi Arabia, to acquire data from unim-
planted patients for comparison, and to continue follow-up 
on the patients included in the present report. Our database 
will be expanded with additional salient variables that will 
allow more detailed comparisons with data from outside 
Saudi Arabia, especially those that may be shown to be re-
lated to risk factors that could have an impact on patient 
management and outcome. This report provides the first data 
from Saudi Arabia on patients implanted with an ICD, estab-
lishes a baseline for future comparisons, and launches explo-
ration of the similarities and differences between our patients 
and those in other populations.  
  In summary, in our sample of Saudi Arabian patients 
selected for ICD insertion following practice guidelines, 
mortality was less than that reported for many RCTs and 
observational studies [4] suggesting a benefit from ICD in-
sertion in these patients. The importance of acquiring addi-
tional data on ICD patients is exemplified by the number of 
reports questioning patient selection and outcome. For ex-
ample, in a recent editorial Brignole summarizes ICD effi-
cacy evidence and then questions whether complications 
may have been underestimated and benefits overestimated 
[21]. He emphasizes the need to develop reliable tools to 
identify patients who should receive ICD therapy. Real 
world data such as ours provide additional information out-
side of clinical trials, and ongoing surveillance and evalua-
tion of outcomes and relevance of prediction models can 
help guide management of these patients. Our work is in line 
with the conclusion of the Guideline Committee that an area 
in need of further research is determining long-term out-
comes and risk factors for patients receiving ICDs in general 
practice, and comparing them with trial populations and at 
academic centers.
1 The acquisition of additional data will 
allow more meaningful comparisons between our data and 
that obtained in RCTs and observational studies in other 
populations. 
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